Literature DB >> 15064006

The lymph node ratio as prognostic factor in node-positive breast cancer.

Mia Voordeckers1, Vincent Vinh-Hung, Jan Van de Steene, Jan Lamote, Guy Storme.   

Abstract

BACKGROUND AND
PURPOSE: The clinical records of the node-positive breast cancer patients treated at our department were reviewed, to evaluate if there is a correlation between the ratio of involved axillary lymph nodes and the overall and cause specific survival. PATIENTS AND METHODS: From 1984 until July 2001, 2073 files from patients with an invasive breast carcinoma were submitted to retrospective analyses. In 810 cases, a node positive status was diagnosed. All pT-stages were included. The total number of dissected nodes (pNtot) and the number of involved nodes (pN+) were available for 741 patients. The ratio of nodal involvement (pN+%) was categorized into three groups, pN+%< or =10% (n = 212) between 11 and 50% (n = 346) and between 51 and 100% (n = 183).
RESULTS: The actuarial overall survival (OS) at 5 and 10 years was, respectively, 78.2 and 59.1%. Cause specific survival (CSS) rates were, respectively, 83.6 and 69.1%. In univariate analyses, age (P = 0.01), grade (P = 0.02), pT-stage (P < 0.0001), chemotherapy (P = 0.0002), the number of involved nodes < or =3 versus >3 (pN+) (P < 0.0001) and ratio pN+% (P < 0.0001) were associated significantly with overall survival. A multivariate analysis using the Cox proportional hazards model found that pN+% was the most significant prognostic factor; pN+lost significance when pN+% was taken into account.
CONCLUSIONS: The percentage of positive lymph nodes in an axillary lymph node dissection appears to be an important prognostic factor for survival. The nodes ratio improved on the absolute numbers of involved axillary lymph nodes for assessment of prognosis.

Entities:  

Mesh:

Year:  2004        PMID: 15064006     DOI: 10.1016/j.radonc.2003.10.015

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  48 in total

1.  Lymph node ratio is more valuable than level III involvement for prediction of outcome in node-positive breast carcinoma patients.

Authors:  Emin Yildirim; Ugur Berberoglu
Journal:  World J Surg       Date:  2007-02       Impact factor: 3.352

2.  Lymphatic-targeted therapy following neoadjuvant chemotherapy: a promising strategy for lymph node-positive breast cancer treatment.

Authors:  Jianghao Chen; Qing Yao; Hui Wang; Bo Wang; Juliang Zhang; Ting Wang; Yonggang Lv; Zenghui Han; Ling Wang
Journal:  Med Oncol       Date:  2015-05-26       Impact factor: 3.064

3.  PET Probe-Guided Surgery in Patients with Breast Cancer: Proposal for a Methodological Approach.

Authors:  Paolo Orsaria; Agostino Chiaravalloti; Alessandro Fiorentini; Chiara Pistolese; Gianluca Vanni; Alessandra Vittoria Granai; Dimitrios Varvaras; Roberta Danieli; Orazio Schillaci; Giuseppe Petrella; Oreste Claudio Buonomo
Journal:  In Vivo       Date:  2017-01-02       Impact factor: 2.155

4.  Lobular ectopic breast carcinoma: A case-report.

Authors:  André Soares; Joana Gonçalves; Isabel Azevedo; Helena G Pereira
Journal:  Rep Pract Oncol Radiother       Date:  2013-04-18

5.  Adequate lymph node examination is essential to ensure the prognostic value of the lymph node ratio in patients with stage III colorectal cancer.

Authors:  Manabu Shimomura; Satoshi Ikeda; Yuji Takakura; Yasuo Kawaguchi; Masakazu Tokunaga; Hiroyuki Egi; Takao Hinoi; Masazumi Okajima; Hideki Ohdan
Journal:  Surg Today       Date:  2011-09-16       Impact factor: 2.549

6.  Prediction of involvement of sentinel and nonsentinel lymph nodes in a Canadian population with breast cancer.

Authors:  Ravi Ramjeesingh; May Lynn Quan; Sandra Gardner; Claire M B Holloway
Journal:  Can J Surg       Date:  2009-02       Impact factor: 2.089

7.  Lymph node ratio may be supplementary to TNM nodal classification in node-positive breast carcinoma based on the results of 2,151 patients.

Authors:  Nüvit Duraker; Bakir Bati; Zeynep Civelek Çaynak; Davut Demir
Journal:  World J Surg       Date:  2013-06       Impact factor: 3.352

8.  Lymph Node Metastasis in the Prognosis of Gastroenteropancreatic Neuroendocrine Tumors.

Authors:  Jacob A Martin; Richard R P Warner; Anne Aronson; Juan P Wisnivesky; Michelle Kang Kim
Journal:  Pancreas       Date:  2017-10       Impact factor: 3.327

9.  An appraisal of lymph node ratio in colon and rectal cancer: not one size fits all.

Authors:  M Medani; Niall Kelly; George Samaha; G Duff; Vourneen Healy; Elizabeth Mulcahy; Eoghan Condon; David Waldron; Jean Saunders; J Calvin Coffey
Journal:  Int J Colorectal Dis       Date:  2013-05-29       Impact factor: 2.571

10.  The prognostic superiority of log odds of positive lymph nodes in stage III colon cancer.

Authors:  Jiping Wang; James M Hassett; Merril T Dayton; Mahmoud N Kulaylat
Journal:  J Gastrointest Surg       Date:  2008-08-16       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.